Radius Health to Announce Third Quarter 2014 Financial Results, Host Conference Call and Live Webcast on Nov 11, 2014

WALTHAM, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2014 financial results on Tuesday, November 11, 2014.

In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Tuesday, November 11, 2014 to discuss the results.

Conference Call Information:

Date: Tuesday, November 11, 2014

Time: 8:00 a.m. ET

Domestic Dial-in Number: 1-877-705-6003

International Dial-in Number: 1-201-493-6725

Live webcast: http://public.viavid.com/player/index.php?id=111563

For those unable to participate in the conference call or webcast, a replay will be available beginning November 11, 2014 at 11:00 a.m. ET until December 11, 2014 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176 or 1-858-384-5517. The replay passcode is 13593871.

A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 30 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.

About Radius Health

Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com

CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.comSource:Radius Health